• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Weight loss: EnteroMedics’ losses widen as company seeks FDA approval

Weight loss: EnteroMedics’ losses widen as company seeks FDA approval

August 1, 2013 By Arezu Sarvestani

Weight loss: EnteroMedics' losses widen as company seeks FDA approval

Neurostimulation systems maker EnteroMedics (NSDQ:ETRM) saw widening losses during its 2nd quarter as the company continues to navigate the FDA process to win approval for the Maestro Rechargeable System’s VBLOC implant, a neurostimulation device for treating obesity.

The pre-revenue company posted losses of $6.3 million, or 11¢ per share, during the 3 months ended June 30, 2013. That compared with $5 million in losses, or 13¢ per share, during the same period last year. That’s a 27.6% widening in net losses, but a 15.4% decrease in per-share losses, attributable mostly to a 43.8% increase in the number of shares.

The company’s per-share earnings fell exactly in line with analysts’ expectations, but there was no movement on Wall Street as ETRM shares were frozen at $1.16 in the hours following the earnings release.

In a separate release EnteroMedics announced that it had signed a $20 million "at-the-market" equity distribution agreement with Canaccord Genuity Inc. listed as the sole agent. The new financing is slated to replace EnteroMedics’ $45 million equity facility with Terrapin Opportunity, according to a press release.

The new funding will help the company as it continues to navigate regulatory pathways and expand its commercial reach.

The Minnesota medical device maker has made big moves in recent months, including finally filing for FDA premarket approval for its flagship VBLOC vagal blocking therapy as a treatment for obesity. The federal watchdog agency earlier this month accepted the application for review.

Check out MassDevice’s Q&A with EnteroMedics CEO Mark Knudson and CFO Greg Lea

The VBLOC system stimulates the vagus nerve, located between the stomach and the esophagus, in order to alter a patient’s eating habits by modifying their physiological cravings. The Maestro system has been on the European market since winning CE Mark approval in 2011.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat, Weight loss Tagged With: 2013, EnteroMedics Inc., Minnesota, Q2

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy